These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 30737243)

  • 21. Development of a Tetravalent T-Cell Engaging Bispecific Antibody Against Glypican-3 for Hepatocellular Carcinoma.
    Yu L; Huang N; Sun H; Yang X; Fu Y; Lang Q; Wang J; Ge L
    J Immunother; 2021 Apr; 44(3):106-113. PubMed ID: 33239522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
    Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
    Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-α.
    Rossi EA; Rossi DL; Cardillo TM; Chang CH; Goldenberg DM
    Mol Cancer Ther; 2014 Oct; 13(10):2341-51. PubMed ID: 25053819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intrahepatically transplanted human cord blood cells reduce SW480 tumor growth in the presence of bispecific EpCAM/CD3 antibody.
    Wulf-Goldenberg A; Eckert K; Fichtner I
    Cytotherapy; 2011 Jan; 13(1):108-13. PubMed ID: 20839999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers.
    Wu Z; Guo HF; Xu H; Cheung NV
    Mol Cancer Ther; 2018 Oct; 17(10):2164-2175. PubMed ID: 30082472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
    Gedeon PC; Schaller TH; Chitneni SK; Choi BD; Kuan CT; Suryadevara CM; Snyder DJ; Schmittling RJ; Szafranski SE; Cui X; Healy PN; Herndon JE; McLendon RE; Keir ST; Archer GE; Reap EA; Sanchez-Perez L; Bigner DD; Sampson JH
    Clin Cancer Res; 2018 Aug; 24(15):3611-3631. PubMed ID: 29703821
    [No Abstract]   [Full Text] [Related]  

  • 29. Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1.
    Kroesen BJ; Nieken J; Sleijfer DT; Molema G; de Vries EG; Groen HJ; Helfrich W; The TH; Mulder NH; de Leij L
    Cancer Immunol Immunother; 1997; 45(3-4):203-6. PubMed ID: 9435874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy.
    Iizuka A; Kondou R; Nonomura C; Ashizawa T; Ohshima K; Kusuhara M; Isaka M; Ohde Y; Yamaguchi K; Akiyama Y
    Oncol Rep; 2016 Nov; 36(5):2625-2632. PubMed ID: 27632942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
    Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
    EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells.
    Tang P; Li L; Zhou Y; Shen CC; Kang YH; Yao YQ; Yi C; Gou LT; Yang JL
    Biotechnol Appl Biochem; 2014; 61(4):376-84. PubMed ID: 24329807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
    Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y
    Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.
    de Jong G; Bartels L; Kedde M; Verdegaal EME; Gillissen MA; Levie SE; Cercel MG; van Hal-van Veen SE; Fatmawati C; van de Berg D; Yasuda E; Claassen YB; Bakker AQ; van der Burg SH; Schotte R; Villaudy J; Spits H; Hazenberg MD; van Helden PM; Wagner K
    Cancer Immunol Immunother; 2021 Jun; 70(6):1569-1581. PubMed ID: 33225419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cell activation and retargeting using staphylococcal enterotoxin B and bispecific antibody: an effective in vivo antitumor strategy.
    Porter LE; Nelson H; Ethem Gecim I; Rice DC; Thibault C; Chapoval AI
    Cancer Immunol Immunother; 1997; 45(3-4):180-3. PubMed ID: 9435868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers.
    Cao Y; Axup JY; Ma JS; Wang RE; Choi S; Tardif V; Lim RK; Pugh HM; Lawson BR; Welzel G; Kazane SA; Sun Y; Tian F; Srinagesh S; Javahishvili T; Schultz PG; Kim CH
    Angew Chem Int Ed Engl; 2015 Jun; 54(24):7022-7. PubMed ID: 25919418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PHE1-based IgG-like antibody platform provides a novel strategy for enhanced T-cell immunotherapy.
    Wang L; Jiang H; Yin X; Liang T; Li G; Ding C; Yang M; Zhang L; Liu J; Xu Y
    Front Immunol; 2024; 15():1415834. PubMed ID: 38933272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia.
    Hoseini SS; Guo H; Wu Z; Hatano MN; Cheung NV
    Blood Adv; 2018 Jun; 2(11):1250-1258. PubMed ID: 29858209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity.
    Rahbar R; Lin A; Ghazarian M; Yau HL; Paramathas S; Lang PA; Schildknecht A; Elford AR; Garcia-Batres C; Martin B; Berman HK; Leong WL; McCready DR; Reedijk M; Done SJ; Miller N; Youngson B; Suh WK; Mak TW; Ohashi PS
    Cancer Immunol Res; 2015 Feb; 3(2):184-95. PubMed ID: 25527357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
    Trinklein ND; Pham D; Schellenberger U; Buelow B; Boudreau A; Choudhry P; Clarke SC; Dang K; Harris KE; Iyer S; Jorgensen B; Pratap PP; Rangaswamy US; Ugamraj HS; Vafa O; Wiita AP; van Schooten W; Buelow R; Force Aldred S
    MAbs; 2019; 11(4):639-652. PubMed ID: 30698484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.